Hexima Ltd · ASX:HXL
Hexima — ShareCafe Small Cap "Hidden Gems" Webinar (April 2022)
19 slides from Hexima's conference presentation, Apr 29, 2022
Slide 1: ASX Announcement: ShareCafe Small Cap Hidden Gems Webinar
HEXIMA LIMITED ASX ANNOUNCEMENT 29 April 2022 SHARECAFE SMALL CAP “HIDDEN GEMS” WEBINAR For personal use only MELBOURNE, AUSTRALIA (29 April 2022): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing pezadeftide (formerly HXP124), a potential new prescription topical treatment
Slide 2: About Onychomycosis
HEXIMA LIMITED ASX ANNOUNCEMENT ABOUT ONYCHOMYCOSIS Onychomycosis is a common fungal nail infection in the nail plate and nail bed. Prevalence of onychomycosis has been estimated at 10% (Japan) and 13.8% (USA). 1 Onychomycosis is an infectious disease and is difficult to treat with a significant hea
Slide 3: Hexima Limited: A game-changing treatment for onychomycosis
SHARE CAFE For personal use only HEXIMA LIMITED (ASX:HXL) A game-changing treatment for onychomycosis 1
Slide 4: Disclaimer
DISCLAIMER For personal use only Summary information events and the future financial performance of Hexima. Forward looking words such as “expect”, “should”, “could”, “may”, This presentation has been prepared by Hexima Ltd and its subsidiaries (collectively “Hexima”). The information in this “predi
Slide 5: Developing a novel topical product addressing a clear unmet need in a large and growing market
HEXIMA LIMITED (ASX:HXL) D E V E LOP IN G A N OV E L T OP ICA L P ROD UCT A D D RE S S IN G A CLE A R UN M E T N E E D IN A L A RGE A N D GROWIN G M A RK E T For personal use only CLINICAL-STAGE, LARGE AND GROWING NOVEL, PROPRIETARY PEZADEFTIDE ADDRESSES WELL-DEFINED INFECTIOUS DISEASE-FOCUSED MARKE
Slide 6: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM P ROV E N T RA CK RE CORD OF D E L IV E RIN G V A LUE For personal use only MICHAEL ALDRIDGE DR. NICOLE VAN DER WEERDEN PROF. MARILYN ANDERSON DR NANCY SACCO PHILLIP ROSE Chief Executive Officer Chief Operating Officer Chief Science Officer Chief Development Officer Chief
Slide 7: Pezadeftide in Action
PEZADEFTIDE IN ACTION For personal use only Click to play animation C O N S U M ER- CENTRI C D E V EL O PM ENT S L I D E 5
Slide 8: Existing Therapies Do Not Meet Consumer Needs
EXISTING THERAPIES DO NOT MEET CONSUMER NEEDS For personal use only CL E A R M A RK E T N E E D F OR A S A F E , CON V E N IE N T A N D M ORE E F F E CT IV E T OP ICA L P ROD UCT TOPICAL Long treatments, ORAL DRUGS Better efficacy but potential TREATMENTS poor efficacy for serious adverse events Pat
Slide 9: Our Solution: Pezadeftide
OUR SOLUTION: PEZADEFTIDE A NATURALLY OCCURRING PEPTIDE PEZADEFTIDE MOLECULE For personal use only IT S UN IQUE P ROP E RT IE S E N A BL E RA P ID N A IL P E N E T RA T ION A N D F UN GA L KILLIN G Pezadeftide is a potent broad-spectrum antifungal peptide that has evolved to kill fungal pathogens •
Slide 10: Successful Phase I Clinical Trial
SUCCESSFUL PHASE I CLINICAL TRIAL 12 12 For personal use only HXP124-ONY-001 – TRIAL DESIGN WEEKS WEEKS Randomised, double blind, vehicle- C OH ORT 3 C OH ORT 4 controlled, ascending dose cohort study Pezadeftide 2% Pezadeftide 2% N=6 patients N=30 patients Patients treated nails daily with (randomi
Slide 11: Phase I: Primary Endpoint Safety and Tolerability
PHASE I: PRIMARY ENDPOINT SAFETY AND TOLERABILITY For personal use only HX P 1 2 4 - ON Y - 0 0 1 – N O S Y S T E M IC A BS ORP T ION A N D N O LOCA L RE D N E S S OR IRRIT A T ION Pezadeftide is safe and well tolerated NOL OR D RE U MGIPS - R EULM ATED N NOO S Y S T E M IC IC A D V EDROL S EORE V E
Slide 12: Phase I: Effective and Rapid Anti-Fungal Activity
PHASE I: EFFECTIVE AND RAPID ANTI-FUNGAL ACTIVITY For personal use only HXP124-ONY-001 – MYCOLOGICAL CURE RATE FOR COHORT 4 30 PATIENTS TREATED AT HIGH DOSE (2%) FOR 6 WEEKS Mycological Cure at 12 weeks 75.0% 69.0% Mycological cure* was achieved in 69% 60.0% of pezadeftide-treated nails in Cohort 4
Slide 13: Phase I: Rapid Clearance of Affected Nail Area
PHASE I: RAPID CLEARANCE OF AFFECTED NAIL AREA For personal use only HXP124-ONY-001 – CLEAR NAIL GROWTH FOR COHORT 4 30 PATIENTS TREATED AT HIGH DOSE (2%) FOR 6 WEEKS Clinical Efficacy over time 15% 14% Pezadeftide cleared the affected nail Proportion of patients with area more effectively than vehi
Slide 14: Rapid and Dramatic Improvement in Appearance of Nails
RAPID AND DRAMATIC IMPROVEMENT IN APPEARANCE OF NAILS Click to play animation N OT ICE A BLE IM P ROV E M E N T IN J US T 2 WE E KS , For personal use only A L M OS T CLE A R IN 1 2 W E E KS Pezadeftide penetrates the nail to kill the fungus, allowing healthy, uninfected nail to grow out • Clear nai
Slide 15: Potential to Deliver the Preferred Solution in a Consumer-Driven Market
POTENTIAL TO DELIVER THE PREFERRED SOLUTION IN A CONSUMER-DRIVEN MARKET For personal use only Convenient, Effective, Safe, topical short course of best-in-class medication therapy mycological cure FOR PATIENTS WHO WANT FOR PHYSICIANS WHO WANT FOR PAYERS WHO WANT An easy-to-apply topical An effective
Slide 16: Phase II Clinical Trial
PHASE II CLINICAL TRIAL HX P 1 2 4 - ON Y - 0 0 2 Results For personal use only Q2 2022 WEEK WEEK WEEK WEEK 13 24 36 40 • Multi-center, randomised, double blind, SHORT COURSE 12 WEEK DAILY DOSING vehicle-controlled study • Primary endpoint safety and tolerability, LOADING/PULSE 1 2 W E E K D A I L Y
Slide 17: Phase II Clinical Trial – Results Q2
PHASE II CLINICAL TRIAL – RESULTS Q2 P L A T F ORM T O A D V A N CE T O P HA S E III DEFINITION For personal use only OF SUCCESS WEEK WEEK 36 0 PHASE I PHASE II COM PA RA BLE OR RESULTS Q2 2022 1 2 - 3 6 W E E KS DA ILY 6 - W E E K DA ILY D OS IN G BE T T E R M YCOLOGICA L 6 WEEKS DAILY DOSING D OS
Slide 18: Pezadeftide: A Potential Solution for a Large and Poorly Served Market
PEZADEFTIDE: A POTENTIAL SOLUTION FOR A LARGE AND POORLY SERVED MARKET For personal use only POORLY SERVED MARKET NEW AND UNIQUE SAFE CONVENIENT EFFECTIVE Affects 14% of the Novel molecule with No systemic effects Easy to apply Efficiently penetrates population unique mode of action the nail No loca
Slide 19: Contacts
CONTACTS For personal use only MIC HAEL D R NIC OLE ALD RID GE VAN D ER WEERD EN CHIE F E X E CUT IV E OF F ICE R CHIE F OP E RA T IN G OF F ICE R m.aldridge@hexima.com.au n.vanderweerden@hexima.com.au hexima.com.au +1 650 452 4684 +61 407 039 983 C O R P ORA T E P R E S ENTA TIO N SLIDE 17
Hexima — ShareCafe Small Cap "Hidden Gems" Webinar (April 2022) on 6ix